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Purpose: Radiation-induced lung disease (RILD), defined as dyspnea in this study, is a risk for patients receiving high-dose thoracic irradiation. 
[A1-4.2] This study is a TRIPOD (Transparent Reporting of A Multivariable Prediction Model for Individual Prognosis or Diagnosis) Type 4 validation 
of previously-published dyspnea models via secondary analysis of esophageal cancer SCOPE1 trial data. [A1-4.1] We quantify the predictive 
performance of these two models for predicting the maximal dyspnea grade ≥ 2 within 6 months after the end of high-dose chemo-radiotherapy 
for primary esophageal cancer. 
Material and methods: [A1-4.3] We tested the performance of two previously published dyspnea risk models using baseline, treatment and 
follow-up data on 258 esophageal cancer patients in the UK enrolled into the SCOPE1 multi-centre trial. The tested models were developed from 
lung cancer patients treated at MAASTRO Clinic (The Netherlands) from the period 2002 to 2011. The adverse event of interest was dyspnea ≥ 
Grade 2 (CTCAE v3) within 6 months after the end of radiotherapy. As some variables were missing randomly and cannot be imputed, 212 patients 
in the SCOPE1 were used for validation of model 1 and 255 patients were used for validation of model 2. The model parameter Forced Expiratory 
Volume in 1s (FEV1), as a predictor to both validated models, was imputed using the WHO performance status. External validation was performed 
using an automated, decentralized approach, without exchange of individual patient data.  
Results: [A1-4.4] Out of 258 patients with esophageal cancer in SCOPE1 trial data, 38 patients (14.7%) developed radiation-induced dyspnea (≥ 
Grade 2) within 6 months after chemo-radiotherapy. The discrimination performance of the models in esophageal cancer patients treated with 
high-dose external beam radiotherapy was moderate, area under curve (AUC) of 0.68 (95% CI 0.55 – 0.76) and 0.70 (95% CI 0.58 - 0.77), 
respectively. The curves and AUCs derived by distributed learning were identical to the results from validation on a local host. 
Conclusion: We have externally validated previously published dyspnea models using an esophageal cancer dataset. FEV1 that is not routinely 
measured for esophageal cancer was imputed using WHO performance status. Prediction performance was not statistically different from 
previous training and validation sets. Risk estimates were dominated by WHO score in Model 1 and baseline dyspnea in Model 2. The distributed 
learning approach gave the same answer as local processing, and could be performed without accessing a validation site’s individual patients-
level data. 
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Introduction 
[A3-4.1] In radiation therapy, high radiation doses are expected to provide better local cancer control, however the 
risk of radiation-induced adverse events is increased. Clinical symptoms of radiation-induced lung disease (RILD) 
include dyspnea, cough, and fever, which can have a serious effect on the patient’s quality of life. [A3-4.2] 
Approximately 10-20% of patients with lung cancer who receive (chemo)-radiotherapy developing moderate to 
severe symptomatic RILD [1]. 
 
[A1-4.2] Radiation-induced dyspnea, the RILD used in the current study, is a side-effect for patients treated with 
high-dose thoracic irradiation. Studies have reported the predictors for radiation-induced dyspnea for lung cancer 
patients treated with (chemo)radiotherapy [2, 3]. The risk factors for RILD include dosimetric factors, clinical factors, 
pathological factors and blood biomarkers [2-16]. [A1-4.5] In our knowledge, there is no published study reporting 
the risk factors of radiation-induced dyspnea for patients with primary esophageal cancer, which might be explained 
by the fact that dyspnea is not routinely assessed during follow-up of esophageal cancer treatment. 
 
[A1-4.2] [A3-4.3] The current study conducted a TRIPOD (Transparent Reporting of A Multivariable Prediction Model 
for Individual Prognosis or Diagnosis) Type 4 validation [17] of previously-published dyspnea models M1 [2] and M2 
[3] via secondary analysis of the SCOPE1 [18, 19] dataset. SCOPE1 was a randomized controlled trial investigating 
the effects of chemo-radiotherapy with and without additional cetuximab in patients with esophageal cancer, 
including follow-up assessments of dyspnea. [A1-4.1] [A1-4.10] We quantify the predictive performance of these 
two models for predicting the maximal dyspnea grade ≥ 2 within 6 months after the end of high-dose chemo-
radiotherapy for primary esophageal cancer. The goal of this study is to verify two hypotheses: (I) that a common 
thoracic RILD model may be feasible for a different index tumour and (II) that it is feasible to perform an external 
validation of a toxicity model between two sites via a distributed learning approach without any exchange of patient-
specific records. 
 
Methods and Materials 
[A1-4.8] Model development cohorts 
[A3-4.6] Patient characteristics in the development and validation cohorts are detailed in Table 2. The first radiation-
induced dyspnea model (M1) [2] was developed from 438 patients with either non-small cell lung cancer (NSCLC) 
Stage I-IIIB or limited disease small cell lung cancer, treated with curatively-intended (chemo)radiotherapy between 
January 2002 till January 2007. Patients in this cohort were predominantly male (328/438, 74.8%) with confirmed 
NSCLC histology (292/438, 66.7%) and a spread of chemotherapy regimens (concurrent 70/438, 16%; sequential 
203/438, 46%; no chemotherapy 159/438, 36%, unspecified 6/438, 1%). RILD, including dyspnea, was scored 
according to CTCAE (v3.0) [20] during radiotherapy (RT) and up to a maximum of 6 months after RT. A range of 
radiotherapy prescribed doses from 46.9 Gy to 79.2 Gy were used, with fraction doses not exceeding 2 Gy. 
[A1-4.8] A second radiation-induced dyspnea model was developed from 259 lung cancer patients treated with 
curatively intended chemo(radiotherapy) between 2008 and 2011, Stage I-IIIB and fractional dose ≤ 3 Gy were used 
to develop a second radiation-induced dyspnea model (M2) [3]. These patients were treated in two hospitals, 
underwent PET/CT for radiotherapy treatment planning and had lung volumes delineated in the planning system. 
This cohort was drawn from an earlier iso-toxicity dose escalation radiotherapy trial (clinicaltrials.gov identifier 
NCT00572325 and NCT00573040) with maximum tumour dose not exceeding 69 Gy. This cohort was predominantly 
male (163/259, 62.9%) with confirmed NSCLC histology (198/259, 75.6%), received concurrent chemotherapy 
(148/259, 57.1%) and had no surgery prior to radiotherapy (236/259, 91.1%). Carboplatin and gemcitabine were 
given for sequential chemotherapy, and cisplatin and etoposide for concurrent chemotherapy. RILD, including 
dyspnea, was scored according to CTCAE (v3.0), by either thoracic physicians or radiation oncologists, at baseline 
and every 3 months following RT. 
External validation cohort 
Two hundred and fifty-eight esophageal cancer patients were enrolled in the SCOPE1 [18, 19] trial from 36 UK 
centres between Feb 7, 2008 and Feb 22, 2012. The inclusion criteria were: non-metastatic, histologically confirmed 
carcinoma of the esophagus (adenocarcinoma, squamous-cell, or undifferentiated carcinoma) or gastro-esophageal 
junction (Siewert type 1 or 2 with <2 cm extension into the stomach); selected for definitive chemo-radiotherapy by 
a designated multidisciplinary team; aged 18 years or older; WHO performance status 0 or 1; stage I-III disease (TNM 
stage 6); and esophageal tumour length < 10 cm as measured by endoscopic ultrasound. The study protocol has 
been published [19] and the trial was coordinated by the Wales Cancer Trials Unit (WCTU). Recruitment in SCOPE1 
was halted due to futility, but follow-up of at least 24 weeks on all recruited patients was available for secondary 
analysis. 
All patients received 4 cycles of cisplatin and capecitabine; 2 cycles were given prior to commencement of RT, and 2 
cycles were given concurrently with RT. This chemotherapy regimen was the most commonly used for esophageal 
cancer treatment in the UK. Chemotherapy dose was modulated for potential hematological toxicity (based on 
neutrophil and platelet counts) and kidney function (based on glomerular filtrate rate). Chemotherapy cycles were 
also withheld for serious non-haematological adverse events until resolution to grade 0 or 1. Half of these patients 
were randomized to additional cetuximab for their chemotherapy. 
All 3D conformal RT plans were based on contrast CT 3 mm slices, for a prescribed dose of 50 Gy in 25 once-daily 
fractions. The esophageal clinical target volume (CTV) was manually delineated as a 2 cm distal and 2 cm proximal 
expansion along the esophagus from the gross primary tumour, and a 1 cm radial expansion. The planning target 
volume was an additional 1 cm proximal-distal expansion from the CTV and an extra 0.5 cm radially. Lung volume 
receiving 20 Gy or higher was constrained to be less than 25% of the total lung volume. 
None of the SCOPE1 patients in the validation cohort received post-RT surgery. The majority of patients were male 
(145/258, 56%) with either mid- or lower-esophageal tumours (226/258, 87.6%) and mean endoscopy-defined 
tumour length of 5.6 cm. Toxicity scoring according to CTCAE (v3.0) was carried out at baseline, during each 
chemotherapy cycle, at 24 weeks and then every 3 months thereafter.  
Previously published dyspnea model parameters 
The model M1 [2] consisted of the following predictors: age, WHO performance status (WHO-PS) before start of RT, 
nicotine use (non-/ex-smoker versus current smoker), FEV1 at baseline and mean lung dose in Gy. The predictors 
used in model M2 [3] were dyspnea score before start of RT, cardiac comorbidity, FEV1 at baseline, tumour location 
(upper versus middle/lower lobes of lung) and sequential chemotherapy. [A3-4.4] Multivariate logistic regression 
analysis was performed to build M1 and M2. The coefficients used in the models are summarized in Table 1. Both 
models defined adverse outcomes as dyspnea grade 2 or higher within 6 months of the end of (chemo)-radiotherapy.  
 
Model assumptions and missing-values imputation 
The previous M1 and M2 had been developed on, and validated in, primary lung cancer patients. However, Forced 
Expiratory Volume (i.e. FEV1), smoking status and lung tumour location (lobe) were uniformly absent from the 
esophageal SCOPE1 dataset. We assumed (based on the trial protocol) that all SCOPE1 patients received 
chemotherapy and we simulated different population scenarios for smoking status. For the model M2, we further 
assumed that unintended radiation dose for esophageal cancers were most analogous to RT for lung tumours in 
lower and/or middle lung lobes. 
Since FEV1 was a predictor in both M1 and M2, we imputed the missing FEV1 measurements of the SCOPE1 patients 
from available data in the model M1 development cohort while blinded to the dyspnea outcome. The imputation 
was based on categorical regression for WHO-PS = 0, WHO-PS = 1 and WHO-PS ≥2. A statistically significant fit for 
FEV1 (in % of total expired volume) was found using the model: 
 
𝐹𝐸𝑉1 (𝑖𝑛 %) = 82.0 𝑖𝑓 𝑊𝐻𝑂 − 𝑃𝑆 = 0 
𝐹𝐸𝑉1 (𝑖𝑛 %) = 74.7 𝑖𝑓 𝑊𝐻𝑂 − 𝑃𝑆 = 1 
𝐹𝐸𝑉1 (𝑖𝑛 %) = 67.3 𝑖𝑓 𝑊𝐻𝑂 − 𝑃𝑆 ≥ 2 
 
Distributed learning 
External validation was performed using the same distributed methodology as published by Deist et al. and Jochems 
et al. [21-23] using the Varian Learning Portal (VLP, Varian Medical Systems, Palo Alto, CA) v1.0. A validation 
algorithm containing model coefficients of M1 and M2 were remotely distributed from the investigator site to the 
validation site via a secured http channel. The SCOPE1 data was parsed using a radiation oncology-specific semantic 
ontology into the Web 3.0-standard resource descriptor format (RDF). The distributed validation algorithm executes 
as a purely site-specific local computation by querying the local RDF repository. Only the summary classification 
results of validation on the SCOPE1 cohort was returned to the investigator site. Security and privacy settings within 
VLP blocked transfer and exposure of patient-level records from the validation site to the investigator. Previous 
studies [21-23] have proven that the algorithm converges to the same result as if all of the patient data was locally 
processed on site by an investigator. The workflow of the distributed learning approach is shown in Figure 1. 
Statistical analysis 
The validation algorithm was deployed in MATLAB, version 9.0 (MathWorks, Natick, MA). Discrimination of 
predictive model was evaluated using the area under the receiver-operator curve (AUC) metric [24]. The AUC metric 
was estimated by bootstrapping (1000 resamples). Calibration of the predictive model was assessed using calibration 
plots [25]. The logistic recalibration was performed through fitting a logistic regression model by the linear predictor 
as the only covariate, which leads to an updated model without changing discrimination performance [26, 27].  
 
Results 
Out of 258 available validation cases in the SCOPE1 dataset, 46 and 3 patients, respectively, were excluded from the 
validation due to missing values of mean lung dose for validation of model M1 and baseline scores of cardiac 
comorbidity and dyspnea for validation of model M2. A total of 212 patients and 255 patients were available to 
externally validate model M1 and M2. In the validation cohort for M1 (V1), there were 31 patients (14.3%) 
manifesting dyspnea grade 2 or higher within 6 months of RT. In the validation cohort for M2 (V2), 38 patients (14.9%) 
manifested dyspnea at the equivalent time point.  
[A1-4.11] [A1-4.12] To investigate the effect of smoking status on the performance of M1 in external validation 
cohort, smoking status was assigned to (i) all smokers, (ii) non-smokers, and (iii) randomly and repeat 1000 
iterations. The test yielded the AUC of 0.68 ± 0.053, 0.68 ± 0.054, and 0.65 ± 0.04 respectively by bootstrap 
sampling. Although the smoking status a missing predictor for esophageal validation cohort, there was no 
statistically significant difference in performance observed based on a bootstrapped Welcoxon test between the 
three scenarios (p-value = 0.34, p -value = 0.17, p-value = 0.11). Therefore, we set it randomly in the validation 
cohort. 
The receiver operator curves (ROCs) of the models on external validation sets V1 and V2 are shown in Figure 2. The 
AUC of both models measured in the previous studies were 0.62 and 0.72 in internal validation and 0.61 and 0.67 
in external validation. [A1-4.14] Compared to the previous studies, the AUC of the two models on V1 and V2 were 
0.68 (95% CI: 0.55-0.76) and 0.70 (95% CI: 0.58-0.77), respectively. [A1-4.12] No statistically significant difference 
in performance was observed between M1 and M2 in the previous training cohorts and current external validation 
cohorts (AUC of M1 0.62 vs 0.68, p = 0.17; AUC of M2 0.72 vs 0.70, p = 0.45, Wilcoxon test). [A3-3.1] The detailed 
assessment of accuracy, sensitivity, specificity, positive predictive value and negative predictive value are shown in 
the Supplementary Table-1. Both prognostic models (M1 and M2) showed poor calibration performance and 
tended towards underestimation of dypsnea in the test population, which is shown in the calibration plots (Figure 
3). Recalibration was performed to update the prognostic models (Figure 4). As expected, the recalibration 
resulted in higher predicted risks without changing the AUCs. The calibration line of the recalibrated M1 was 
shifted be closer to the ideal line, whereas the calibration line of M2 was not improved overall by the recalibration. 
 
Discussion 
The current study has tested two previously-published RILD models M1 and M2 [2, 3] on the independent validation 
sets V1 and V2 of the SCOPE1 trial data [18, 19], which comprises esophageal cancer patients treated with chemo-
radiotherapy. Moreover, external validation was successfully implemented using an automated and decentralized 
approach without exchange of individual patient data. 
 
As is well known, high-dose of thoracic radiation can often provide better local tumour control and survival for 
patient with cancer. Previous studies have shown that additional radiation in an appropriate range can improve 
locoregional tumour control and increase survival of patients with lung cancer [28-30]. However, the irradiation dose 
in the radiotherapy treatment of esophageal cancer can have an adverse effect on lung tissue resulting in RILD, such 
that it leads to disutility of care and have a serious negative impact on patients’ quality of life. RILD usually manifests 
itself in the acute (<6 months) phase as radiation pneumonitis (RP) and in the later (> 6 months) phase as chronic 
pulmonary fibrosis [31-33]. RP is the most common dose-limiting complication of thoracic radiation with clinical 
symptoms such as dyspnea, cough, and sometimes fever [34]. Therefore, it is a trade-off between better tumour 
control (i.e., better survival or lower death rate) and RILD. 
 
The prognostic models are regarded as the basis of clinical decision support systems (CDSS) [35] that can relieve 
clinicians from the pressure of analysing the large volume of publications and data by applying discoveries from 
research into a data-analytics architecture [36, 37]. However, it is difficult to apply the results of research in clinical 
practice to predict which patients with esophageal cancer will likely suffer from RILD. The first reason is that many 
studies have investigated the risk predictors of RILD including dosimetric, clinical, pathological factors or blood 
biomarkers [2-16], but results between studies are highly variable or even contradictory [34, 38]. In the meantime, 
there is no standardized lung toxicity grading system and no standard data models (so-called umbrella protocols) to 
guide prospective collection on routine cases. On the other hand, few publications report the risk predictors of RILD, 
(e.g., severe dyspnea) for patients with esophageal cancer. This difficulty might be explained by the fact that dyspnea 
is not routinely assessed during diagnosis and prognosis of esophageal cancer.  
  
At present, it is widely acknowledged that a prognostic model cannot be applied in clinical practice before its 
feasibility and practicability have been certified via validation on different levels [17, 39]. External validation of a 
prognostic model should be performed on an/some independent cohort(s), because most models present optimistic 
results in the development cohorts. Validation of prognostic models involves two aspects [40]. First, generalizability 
of a prognostic model can be described by validation on similar (reproducibility) or different (transferability) cohorts. 
The similarity or difference between cohorts refer to temporal, geography, methodology or investigator, which aims 
to distinguish from the development cohort of the original model [17, 41, 42]. One primary goal of the current study 
to investigate the transferability of two previously-published lung toxicity models M1 and M2 under these “different” 
situations. 
 
Second, accuracy performance of a prognostic model shows the statistical validity [43]. Discrimination and 
calibration [25], in general, measure the accuracy performance. (i) Discrimination describes whether an individual 
with higher predictive probability is indeed experience RILD more often. Area under the receiver-operator curve 
(AUC) [24] was used to assess the discrimination performance, which is shown in Figure 2. The model M1 achieved 
a better discrimination performance (i.e., AUC) on V1 compared to the internal and external validation performed 
in the original study. The M2 obtained a better AUC on V2 than the AUC of the external validation but was 
consistently degraded in AUC from the internal validation of the original study. (ii) Calibration reflects the agreement 
between observed event and predicted risk. The calibration performance was assessed by calibration plots, which 
are shown in Figure 3. A perfectly calibrated model means that the predicted probabilities of RILD are identical to 
the observed frequencies of RILD for all patient groups. The calibration-in-the-large (i.e., intercept) of M1 and M2 
were 3.79 (p=0.08) and 0.42 (p=0.46), and calibration slope were 2.60 (p=0.007) and 1.99 (p<0.0001), which indicates 
that predicted risks of M1 and M2 in SCOPE1 were systematically under-estimated and there was insufficient 
variation of covariates in V1 and V2 sets. A possible explanation may involve systematic under-reporting of clinical 
toxicity in the retrospectively-collected training sets. By testing different assumptions about smoking status in the 
test cohorts, there is no evidence to support an effect of smoking in either aggravating or protecting against dyspnea. 
It is also possible that the original models in lung cancer were improperly calibrated, but there was no additional 
information in the published articles to confirm this. However, a systematic underestimation of the dyspnea rate 
would be consistent with an offset error in the linear fit of FEV1 using the WHO performance score. This potential 
source of error could only be circumvented by measuring the FEV1 for the SCOPE1 test cases, which was not done. 
To correct poor calibration performance, recalibration can be performed through fitting a logistic regression model 
by the linear predictor as the only covariate, which leads to an updated model without changing discrimination 
performance [26, 27, 44]. The calibration performance of M1 was moderate after conducting recalibration. The M2 
model still had poor calibration performance even after recalibration, which means care should be taken applied in 
real clinical practice.  
 
Strengths of the analysis 
[A3-4.9] The SCOPE1 trial data, as an independent validation cohort, satisfied the conditions of separation in terms 
of temporal (different treatment time of patients in SCOPE1 and previous training cohorts), geographic (different 
regions, Cardiff vs Netherlands) and investigator (different people from different institutes) from the development 
cohort of lung cancer. It means that the SCOPE1 was a sufficiently challenging dataset to externally validate the 
transferability of a prediction model between different index cancers. Second, we have shown the RILD models (e.g., 
M1) can be robustly transferred to other diseased sites (e.g., esophagus) that only having the incidentally irradiated 
normal tissues in common without losing accuracy performance. Thirdly, this study was implemented using an 
automated and distributed approach without exchanging any patient data. Due to the confidentiality of patient data, 
local laws and technical issues, it can be prohibitively difficult to exchange patient data among hospitals. Compared 
to the centralized learning approach, the distributed learning approach can avoid privacy-related issues by sending 
research questions among institutes. The distributed learning can be achieved by transferring a machine learning 
algorithm to a target site and returning the results back to the sender rather than transferring real data. This process 
means knowledge exchange occurs without important clinical data leaving hospitals and there is no loss of validation 
integrity when performed distributed learning. 
 
Weakness of the analysis 
The current study has some limitations worthy of mention. First, some outcome data and predictor variables were 
missing in the validation cohorts, and data was not missing completely at random. If the missing data were 
compulsory predictors for the prognostic models (M1 and M2) and cannot be imputed, the corresponding patients 
had to be removed from the validation cohort. In addition to this, there are non-random missing data, which might 
be explained by the fact that the information about lung cancer were not be registered for patients with esophageal 
cancer in the SCOPE1 trial, such as tumour location, smoking status, and FEV1. For tumour location, we assumed that 
all of these esophageal cancer patients treated with radiation were similar to lung patients with a tumor in the lower 
lung lobe. For the missing FEV1, WHO-PS was used to impute as mentioned above. Second, there are some 
differences between the development (D1 and D2) and validation cohorts (V1 and V2), of which the effect on the 
model performance are the subject of future work. . (i) SCOPE1 randomized half of the patients between cetuximab 
or not, whereas patients in D1 and D2 were not treated with cetuximab. (ii) All patients received chemo-radiotherapy 
in V1 and V2, while only 273 (63.2%) and 197 (76.1%) patients received chemotherapy in D1 and D2. (iii) The numbers 
of patients in D2 with baseline score 0, 1, ≥2 are 78 (30.1%), 140 (54.1%) and 48 (14.7%), whereas these numbers in 
V2 are 238 (93.33%), 14 (5.49%) and 3 (1.18%). It indicates that more patients had low-grade or no dyspnea overall 
in V2 compared with patients in D2. The effects of these uncertainties on the performance of prognostic models M1 
and M2 remain unclear and are the subject of future studies.  
 
[A1-2] Finally, another potential limitation is about the validated models’ selection, that is the performance of M1 is 
moderate in terms of AUC and M2 does not include lung dose volume parameters. Although the discrimination 
performance of M1 is moderate, we found it achieved a similar and even better discrimination performance in the 
external validation cohort, which demonstrated that M1 has a good generalization. M2 was developed using 
multivariable regression approach. The original study [3] did evaluate mean lung dose and V20Gy as potential risk 
factors, but then dropped it from the final regression model because their contributions were small and/or could 
not be shown to be statistically significant. 
Future work 
Future work would involve two aspects. First, the M1 could be tested on a similar dataset to validate the 
reproducibility. Second, we would like to re-train the lung toxicity model on D1 and D2 via combining different types 
of features, such as image, pathological or generic features. 
 
Conclusion 
In this study, we have externally validated previously published dyspnea models using an esophageal cancer dataset. 
First, the discrimination performance of the models in esophageal cancer patients treated with high-dose external 
beam radiotherapy are moderate, AUC of 0.68 (95% CI 0.55 – 0.76.) and 0.70 (95% CI 0.58 -0.77), respectively. Second, 
risk estimates were strongly determined by WHO score in Model 1 and baseline dyspnea in Model 2. Third, the 
distributed learning approach gave the same answer as local validation but is feasible without accessing a validation 
site’s patient-level data. Finally, the clinical contribution of the dyspnea prognostic model is that it would help 
doctors to identify patients who will likely suffer from severe dyspnea and who could therefore benefit from dose 
de-escalation in (chemo)-radiotherapy. Although we cannot conclude that a common thoracic RILD model is feasible 
for a different primary tumour, it can be deemed as a “benchmark” for further investigation of RILD prognostic 
models of thoracic tumour. 
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[A1-4.18] [A1-4.19] [A3-4.6] Table 1: Patient characteristics.  
Variable D1 
Maastro clinic (N=438) 
D2 
Maastro clinic 
(N=259) 
V1 
 SCOPE1 
 (N = 212) 
V2 
SCOPE1  
(N = 255) 
Gender 
Male 
Female 
 
328 (74.9%) 
110 (25.1%) 
 
163 (62.9%) 
96 (37.1%) 
 
120 (56.6%) 
92 (43.4%) 
 
145 (56.2%) 
113 (43.8%) 
Age (years) Mean 68 (SD 9) Mean 67.5 (SD 10.1) Mean 72.8 (SD 8.95) Mean 72.9 (SD 9.02) 
Smoking status 
Current smoker 
 
77 (29.7%) 
 
NA 
 
NA 
 
NA 
WHO-PS 
0 
1 
≥2 
 
119 (27.9%) 
223 (52.3%) 
84 (19.7%) 
 
63 (24.3%) 
153 (59.1%) 
43 (16.6%) 
 
110 (51.9%) 
102 (48.1%) 
0 
 
130 (50.9%) 
125 (49.1%) 
0 
CCI 
0 
1 
2 
≥3 
Missing 
 
132(30.9%) 
128 (30.0%) 
95 (22.2%) 
72 (16.8%) 
0 
 
No: 184 (71.0%) 
Yes: 75 (29%) 
 
NA 
 
NA 
Cardiac comorbidity 
No 
Yes 
Missing 
 
132(30.9%) 
295 (69.0%) 
1 (0.1%) 
 
No: 184 (71.0%) 
Yes: 75 (29.0%) 
 
208 (98.1%) 
2 (1.0%) 
2 (1.0%) 
 
252 (98.8%) 
3 (1.2%) 
NA 
Baseline dyspnea score 
0 
1 
≥2 
Missing 
 
NA 
NA 
NA 
NA 
 
78 (30.1%) 
140 (54.1%) 
38 (14.7%) 
3 (1.1%) 
 
197 (92.9%) 
10 (4.7%) 
3 (1.4%) 
2 (1.0%) 
 
238 (93.3%) 
14 (5.5%) 
3 (1.2%) 
NA 
dyspnea score after RT 
0 
1 
≥2 
Missing 
 
NA 
NA 
NA 
NA 
 
NA 
NA 
NA 
NA 
 
135 (63.7%） 
46 (21.7%) 
31 (14.3%) 
 
164 (64.3%） 
53 (20.8%) 
38 (14.9%) 
FEV1 (%) Mean 70.0 (SD 23) Mean 76.0 (SD 21.86) NA NA 
Chemotherapy 
No 
Yes 
Missing 
 
159 (36.8%) 
273 (63.2%) 
0 
 
44 (17.0%) 
197 (76.1%) 
18 (6.9%) 
 
0 
212 (100%) 
0 
 
0 
255 (100%) 
0 
Tumour location 
Lower/Middle lobe 
Upper lobe  
 
245 (56.3%) 
190 (43.7%) 
 
76 (29.3%) 
83 (32.1%) 
 
NA 
NA 
 
NA 
NA 
Mean lung dose (Gray) 
Min 
Max 
Median 
Missing 
13.5 (SD 4.5) 
 
 
15.7 (SD 4.44) 9.8 (SD 2.8) 
0.01 
17.9  
10.0 
NA 
9.83 (SD 2.8) 
0.01 
17.9  
9.9 
45 (9.80%) 
V20 (%) Mean 21.0 (SD 7.3) Mean 25.5 (SD 9.9) NA NA 
Abbreviations: WHO-PS, World Health Organisation performance scale; CCI, Charlson comorbidity index; FEV1, forced expiratory volume (1s); 
V20, volume of the lung receiving ≥ 20 Gy, SD, standard deviation. D1and D2 are development cohorts for the validated model 1[2] and model 2 
[2]. V1 and V2 are validation cohorts. 
 
 
 
[A1-4.16] [A1-4.17] Table 2: Coefficients (odds ratios of predictors) obtained from the multivariate logistic regression in the 
first (M1) [2] and second (M2) [3] dyspnea models. 
Variable Model coefficients (M1) Model coefficients (M2) 
Intercept -2.2767 -1.512 
Performance status 
WHO-PS = 1 
WHO-PS ≥ 2 
 
0.28 
0.57 
 
- 
- 
Current smoker -0.45 - 
Age 0.02 - 
Mean Lung Dose 0.05 - 
Baseline dyspnea - 0.990 
Cardiac comorbidity - 0.826 
Sequential chemotherapy - 0.610 
Tumour in middle/lower lung lobe - -0.290 
Baseline FEV1 -0.02 -0.007 
 
 
 Figure 1: Generalized workflow of the distributed learning approach used in this study. D1 and D2 indicate the development 
cohorts used to develop the original RILD models M1 and M2. V1 and V2 indicate the validation cohorts for M1 and M2, 
respectively. CI indicates confidence interval.  
 
   a                                                           b 
[A3-4.5] Figure 2: Receiver operating characteristic curves of the prognostic models a: M1 and b: M2 with 95% CI of area under 
the receiver-operator curve (AUC). CI: confidence interval. 
 [A1-4.20] Figure 3: Calibration and recalibration plots of M1 and M2 on the V1 and V2 cohorts, respectively. Perfect 
calibration is represented by the solid line through the origin with slope =1. Ten quantile groups were used to 
compare the predicted probability and the corresponding observed frequencies with a triangle. Histogram of 
outcomes (i.e., dyspnea or no dyspnea) is shown below each plot. a: calibration-in-the large; b: calibration slop; c: 
area under the receiver-operator curve (AUC). 
 
